课题基金 / 基金详情

Modulating Calcineurin Signaling Pathways in Muscle

Modulating Calcineurin Signaling Pathways in Muscle
调节肌肉中的钙调神经磷酸酶信号通路
批准号:
8274860
负责人:
Beverly A Rothermel
金额:
$38.86万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-12-13 至 2014-05-31

项目摘要

项目成果

Beverly A Rothermel的其他基金

相似基金

相关文献

中文摘要
翻译
肥厚性和缺血性心脏病在这个国家和全球都已经达到了流行的程度。 因此,迫切需要新的、更有效的治疗方法。钙调神经磷酸酶是一种受钙调节的 在压力下促进心脏肥大生长和重塑的蛋白质磷酸酶。我们的 实验室发现了最近被重新命名为钙调神经磷酸酶调节因子的RCAN蛋白家族。我们 证实RCAN结合并抑制心肌和骨骼肌中钙调神经磷酸酶的活性。我们向大家展示了 RCAN1在转基因小鼠中的高表达通过以下方式保护心脏免受各种压力的影响 抑制心肌梗死后肥大生长和心力衰竭的进展。战略以实现 因此,增加心脏中RCAN的表达或活性可能对治疗有临床价值 和预防心脏病。该提案是对我们的RO1的竞争性续订,标题为 肌肉中的钙调神经磷酸酶信号通路。我们最初目标的实现做出了重大贡献 了解rcan对钙调神经磷酸酶的调节及其生物学意义。我们的发现已经 美国在令人兴奋的新方向上,可能将RCAN1对钙调神经磷酸酶的调节与缺氧或氧化应激联系起来 回应。重要的是,我们和其他人最近发现,心脏的梗塞面积更大。 缺血再灌注(I/R)后缺乏RCAN1的小鼠。总之,这些发现表明,RCAN1既可以 限制肥大生长以应对压力超负荷并减少I/R造成的损害我们的新目标 解决从这些发现中产生的重要问题。具体目标1:确定 调控RCAN1.4表达的CAATT/增强子结合蛋白β(C/EBPB)及其检测 参与心脏肥厚性重塑。在这一节中,我们将测试 C/EBPB,它在心脏缺氧时被激活,以控制RCAN1.4的表达并确定 C/EBPb活性是否影响钙调神经磷酸酶信号或心肌肥厚。具体目标2:界定 RCAN1亚型与泛素/蛋白酶体系统的相互作用 在心肌细胞肥大的环境中贡献异构体的特定功能。我们已经确定了 两种不同类型的泛素连接酶复合体,它们与一种RCAN1亚型特异相互作用,但不与RCAN1亚型相互作用 其他的。Cullin 4A E3连接酶复合体(Cul4A)与RCAN1.4相互作用,而von Hippel-Lindau因子 作为低氧反应的组成部分,VHL与RCAN1.1相互作用。具体目标3:界定 RCAN1保护心肌细胞免受氧化损伤的机制。在这部分中 我们将使用体外和体内技术来测试RCAN1是否保护心肌细胞 防止氧化损伤,并评估目标1和2中研究的机制在这一过程中的参与情况。 这些研究旨在阐明RCAN1的机制、调节和生理作用,并创建 这是治疗和预防心脏病的新疗法的基础。在美国,导致心力衰竭的心血管疾病是导致死亡的主要原因 尽管应用了最先进的治疗方法,但患病率仍在上升。很明显,有必要对 开发新的治疗方法。这项提案将提供关于一个家庭的重要信息 保护心脏的内源性蛋白质称为钙调神经磷酸酶(RCAN)。这些研究将 阐明rcan蛋白的机制、调节和生理作用,为新的 调节钙调神经磷酸酶的治疗方法,钙调神经磷酸酶是一种参与多种疾病进展的蛋白质 包括心脏病和老年痴呆症在内的病理。
英文摘要
Hypertrophic and ischemic heart disease has reached epidemic proportions both in this country and globally. As a result, there is urgent need for new and more effective therapies. Calcineurin is a calcium-regulated protein phosphatase that promotes hypertrophic growth and remodeling of the heart under stress. Our laboratory identified a family of proteins recently renamed RCANs for Regulators of Calcineurin. We demonstrated that RCANs bind to and inhibit calcineurin activity in heart and skeletal muscle. We showed that increased expression of RCAN1 in transgenic mice protects the heart from a wide variety of stresses by blunting both hypertrophic growth and the progression to heart failure after myocardial infarction. Strategies to increase the expression or activity of RCANs in the heart may therefore have clinical value for the treatment and prevention of heart disease. This proposal is a competitive renewal of our RO1 entitled "Modulating Calcineurin Signaling Pathways in Muscle." Accomplishment of our initial goals has contributed significantly toward understanding RCAN's regulation of calcineurin and its biological significance. Our findings have taken us in exciting new directions that may link regulation of calcineurin by RCAN1 to hypoxic or oxidative stress responses. Importantly, we, and others, have recently found that the area of infarct is larger in the hearts of mice lacking RCAN1 after ischemic-reperfusion (I/R). Together these findings suggest that RCAN1 can both limit hypertrophic growth in response to pressure overload and reduce damage from I/R. Our new goals address important questions that have grown out of these findings. Specific Aim 1: To determine the role of the CAATT/enhancer binding protein beta (C/EBPb) in regulating RCAN1.4 expression and test its involvement in hypertrophic remodeling of the heart. In this section we will test the ability of C/EBPb, which is activated in response to cardiac hypoxia, to control RCAN1.4 expression and determine whether C/EBPb activity influences calcineurin signaling or cardiac hypertrophy. Specific Aim 2: To define interactions of RCAN1 isoforms with the ubiquitin/proteasome system and to test whether these contribute isoform-specific functions in the setting of cardiomyocyte hypertrophy. We have identified two different classes of ubiquitin ligase complexes that interact specifically with one RCAN1 isoform but not the other. A cullin 4A E3 ligase complex (Cul4A) interacts with RCAN1.4, whereas the Von Hippel-Lindau factor (VHL), an integral component of hypoxic responses, interacts with RCAN1.1. Specific Aim 3: To define mechanisms through which RCAN1 protects cardiomyocytes from oxidative damage. In this portion of the proposal we will use both in vitro and in vivo techniques to test whether RCAN1 protects cardiac myocytes from oxidative damage and assess the involvement of mechanisms studied in Aims 1 and 2 in this process. These studies are designed to clarify the mechanism, regulation and physiological role of RCAN1 and create the basis for novel therapeutic approaches to the treatment and prevention of heart disease. Cardiovascular disease leading to heart failure is the leading cause of death in the Unites States and is increasing in prevalence despite the application of state-of-the-art therapies. There is a clear need for the development of new therapies. This proposal will provide important information regarding a family of endogenous proteins that protect the heart called Regulators of Calcineurin (RCANs). These studies will clarify the mechanism, regulation and physiological role of RCAN proteins and create the basis for novel therapeutic approaches to regulating calcineurin, a protein involved in the progression of a wide range of pathologies including heart disease and Alzheimers.
期刊论文(42)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.yjmcc.2014.06.015
发表时间: 2014-10
期刊: Journal of molecular and cellular cardiology
影响因子: 5
作者: [Ibarra C, Vicencio JM, Varas-Godoy M, Jaimovich E, Rothermel BA, Uhlén P, Hill JA, Lavandero S]
通讯作者: Lavandero S
DOI: 10.1016/j.bbamcr.2015.02.005
发表时间: 2015-05
期刊: Biochimica et biophysica acta
影响因子: --
作者: [Westermeier F, Navarro-Marquez M, López-Crisosto C, Bravo-Sagua R, Quiroga C, Bustamante M, Verdejo HE, Zalaquett R, Ibacache M, Parra V, Castro PF, Rothermel BA, Hill JA, Lavandero S]
通讯作者: Lavandero S
DOI: 10.1161/circresaha.108.186551
发表时间: 2008-12-05
期刊: CIRCULATION RESEARCH
影响因子: 20.1
作者: [Rothermel, Beverly A., Hill, Joseph A.]
通讯作者: Hill, Joseph A.
DOI: 10.4161/auto.6756
发表时间: 2008-10
期刊: Autophagy
影响因子: 13.3
作者: [Rothermel BA, Hill JA]
通讯作者: Hill JA
共 22 条
    Elevated mitochondrial fusion and function in Down syndrome - Revision - 2
    • 批准号:
      10645484
    • 项目类别:
    • 资助金额:
      $16.49万
    • 财政年份:
      2022
    • 负责人:
      Beverly A Rothermel
    • 依托单位:
    Elevated mitochondrial fusion and function in Down syndrome
    • 批准号:
      9894475
    • 项目类别:
    • 资助金额:
      $202.19万
    • 财政年份:
      2019
    • 负责人:
      Beverly A Rothermel
    • 依托单位:
    Training Core
    • 批准号:
      10473538
    • 项目类别:
    • 资助金额:
      $15.96万
    • 财政年份:
      2015
    • 负责人:
      Beverly A Rothermel
    • 依托单位:
    Training Core
    • 批准号:
      10684156
    • 项目类别:
    • 资助金额:
      $15.96万
    • 财政年份:
      2015
    • 负责人:
      Beverly A Rothermel
    • 依托单位:
    海外基金